Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H8O2 |
Molecular Weight | 148.1586 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C1=CC=CC=C1
InChI
InChIKey=WBYWAXJHAXSJNI-VOTSOKGWSA-N
InChI=1S/C9H8O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-7H,(H,10,11)/b7-6+
Cinnamic acid is a polyphenol found in cinnamon oil and used in commercial flavorings. Recent studies have shown the pharmacological properties of cinnamic acid and its derivatives, including hepatoprotective, anti-oxidant, and anti-diabetic activities. In preclinical studies cinnamic acid demonstrated to be a promising candidate for the treatment ob obesity and diabetes. The mechanism of action of cinnamic acid in obesity is explained by its ability to inhibit lipases and ACE (angiotensin-converting enzyme). However, there are several hypotesis regarding the effect of cinnamic acid in diabetes: cinnamic acid enhances glucose-induced insulin secretion, prevents palmitic acid-induced lipotoxicity, inhibits palmitic acid-induced alteration of lipogenic gene and protein expression (AMPK, SREBP-1c, FAS, ACC), inhibits DPP IV, exhibits an additive effect on the uptake of glucose, stimulates adiponectin secretion, etc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Lipid digestive enzymes Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
|||
Target ID: P12821 Gene ID: 1636.0 Gene Symbol: ACE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
|||
Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28230764 |
|||
Target ID: P18031 Gene ID: 5770.0 Gene Symbol: PTPN1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26139902 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. | 1999 Mar 2 |
|
Simultaneous analysis of the di(2-ethylhexyl)phthalate metabolites 2-ethylhexanoic acid, 2-ethyl-3-hydroxyhexanoic acid and 2-ethyl-3-oxohexanoic acid in urine by gas chromatography-mass spectrometry. | 2001 Jul 15 |
|
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. | 2001 Mar |
|
Genetically engineered Pseudomonas: a factory of new bioplastics with broad applications. | 2001 Oct |
|
Selective growth inhibitor toward human intestinal bacteria derived from Pulsatilla cernua root. | 2001 Oct |
|
Organic acids in the second morning urine in a healthy Swiss paediatric population. | 2003 Dec |
|
Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment. | 2003 May |
|
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. | 2004 Apr |
|
Esters, amides and substituted derivatives of cinnamic acid: synthesis, antimicrobial activity and QSAR investigations. | 2004 Oct |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). | 2009 May |
|
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. | 2010 Oct 6 |
|
Transformation of cinnamic acid from trans- to cis-form raises a notable bactericidal and synergistic activity against multiple-drug resistant Mycobacterium tuberculosis. | 2011 Jun 14 |
|
Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus. | 2011 May |
|
Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents. | 2012 Aug |
|
Amelioration of cyclophosphamide induced myelosuppression and oxidative stress by cinnamic acid. | 2012 Feb 5 |
Patents
Sample Use Guides
In a preclinical study cinnamic acid was administered orally to rats at a dose of 5 and 10 mg/kg (diabetes model). In a preclinical model of obesity/hypertension cinnamic acid was given at 30 mg/kg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19685889
To determine the effect of cinnamic acid on glucose uptake FL83B cells were suspended in HBSS
containing 5 mM glucose and 5.0 ug/mL insulin. Each 20 uL aliquot of the cell suspension was incubated with the mixture of 20 uL of 12.5 uM cinnamic acid and 20 uL of HBSS at 37 celsius degrees for 30 min with constant shaking. Glucose uptake in mouse liver FL83B cells treated with cinnamic acid (472.8 (8.9 cpm/mg of protein) is
2.3 and 2.0 times of the basal uptake value (240.6 (20.2 cpm/mg of protein), respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
2727 (Number of products:1)
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
||
|
FDA ORPHAN DRUG |
782820
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
||
|
CFR |
21 CFR 172.515
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
||
|
FDA ORPHAN DRUG |
802320
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
||
|
FDA ORPHAN DRUG |
783920
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
||
|
JECFA EVALUATION |
CINNAMIC ACID
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
210-708-3
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
ALTERNATIVE | |||
|
35697
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
1368650
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
140-10-3
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
1368649
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000090683
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
623441
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
444539
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
23248
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
187
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
m3569
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | Merck Index | ||
|
44010
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
27386
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
CINNAMIC ACID
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
U14A832J8D
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
DTXSID5022489
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
SUB29136
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
1133933
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
9189
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
C029010
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
U14A832J8D
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
205-398-1
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
PRIMARY | |||
|
621-82-9
Created by
admin on Fri Dec 15 16:46:45 UTC 2023 , Edited by admin on Fri Dec 15 16:46:45 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY |
ACTIVE MOIETY
METABOLITE (PARENT)
PARENT (METABOLITE)
SALT/SOLVATE (PARENT)